PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis.
- Author:
Youjeong SEO
1
;
Yeon Hee PARK
;
Jin Seok AHN
;
Young Hyuck IM
;
Seok Jin NAM
;
Soo Youn CHO
;
Eun Yoon CHO
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; ErbB-2 receptor; Mutation; Neoadjuvant therapy; Phosphatidylinositol 3-kinases
- MeSH: Breast; Breast Neoplasms; Disease-Free Survival; Drug Therapy; Epidermal Growth Factor*; Humans; Humans*; Multivariate Analysis; Neoadjuvant Therapy*; Phosphatidylinositol 3-Kinases; Polymerase Chain Reaction; Receptor, Epidermal Growth Factor*; Receptor, ErbB-2
- From:Journal of Breast Cancer 2018;21(4):382-390
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: PIK3CA mutation is considered to be a possible cause for resistance to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the association between PIK3CA mutations and the outcome of NAC in HER2-positive breast cancers. METHODS: A total of 100 HER2-positive breast cancer patients who had undergone NAC and surgery between 2004 and 2016 were examined. Mutation status was sequentially assessed in pre-NAC, post-NAC, and recurrent specimens taken from these patients. RESULTS: PIK3CA mutations were identified in the sequential specimens of 17 patients (17.0%). These 17 patients experienced shorter disease-free survival (DFS) than the rest of the patients (58.3 months vs. 119.3 months, p=0.020); however, there was no significant difference in pathologic complete response (pCR) and overall survival (OS) (pCR, 17.6% vs. 33.7%, p=0.191; OS, 84.5 months vs. 118.0 months, p=0.984). While there was no difference in pCR between the wild-type and mutant PIK3CA groups in pre-NAC specimens (25.0% vs. 31.8%, p=0.199), PIK3CA mutations correlated with lower pCR in post-NAC specimens (0.0% vs. 24.3%, p < 0.001). Multivariate analysis revealed significantly worse DFS in the mutant PIK3CA group than in the wild-type group (hazard ratio, 3.540; 95% confidence interval, 1.001–12.589; p=0.050). Moreover, the DFS curves of the change of PIK3CA mutation status in sequential specimens were significantly different (p=0.016). CONCLUSION: PIK3CA mutation in HER2-positive breast cancer was correlated with a lower pCR rate and shorter DFS. These results suggest that PIK3CA mutation is a prognostic marker for NAC in HER2-positive breast cancer, especially in post-NAC specimens.
